Literature DB >> 3130424

Meningococcal carriage, meningococcal disease and vaccination.

M K Hassan-King1, R A Wall, B M Greenwood.   

Abstract

Group A meningococcal carriage rates were determined 6 months before and 6 and 18 months after a mass vaccination campaign with a combined group A and group C meningococcal polysaccharide vaccine in a rural area of The Gambia. During the first pre-vaccination survey, performed during an outbreak of meningococcal disease, the carriage rate was high (16%). The carriage rate remained high during a second survey made 6 months after a vaccination campaign that covered approximately 90% of the study population. A year later very few group A meningococcal carriers were found. Membrane protein patterns of isolates obtained before and after vaccination were similar. We conclude that vaccination had little influence on the carriage rate of group A meningococci but that this was influenced by changes in herd immunity or by other unidentified factors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3130424     DOI: 10.1016/s0163-4453(88)96117-8

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  15 in total

Review 1.  Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa.

Authors:  Idris Mohammed; Garba Iliyasu; Abdulrazaq Garba Habib
Journal:  Pathog Glob Health       Date:  2017-01-12       Impact factor: 2.894

Review 2.  Review of meningococcal vaccines with updates on immunization in adults.

Authors:  Yorgo C Zahlanie; Moza M Hammadi; Soha T Ghanem; Ghassan S Dbaibo
Journal:  Hum Vaccin Immunother       Date:  2014-02-05       Impact factor: 3.452

3.  Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study.

Authors:  S M Niaz Arifin; Christoph Zimmer; Caroline Trotter; Anaïs Colombini; Fati Sidikou; F Marc LaForce; Ted Cohen; Reza Yaesoubi
Journal:  Med Decis Making       Date:  2019-07-03       Impact factor: 2.583

4.  Comparison of different vaccines and induced immune response against Campylobacter jejuni colonization in the infant mouse.

Authors:  A G Abimiku; J M Dolby; S P Borriello
Journal:  Epidemiol Infect       Date:  1989-04       Impact factor: 2.451

5.  Clonal groupings in serogroup X Neisseria meningitidis.

Authors:  Sébastien Gagneux; Thierry Wirth; Abraham Hodgson; Ingrid Ehrhard; Giovanna Morelli; Paula Kriz; Blaise Genton; Tom Smith; Fred Binka; Gerd Pluschke; Mark Achtman
Journal:  Emerg Infect Dis       Date:  2002-05       Impact factor: 6.883

6.  Development and evaluation of an improved mouse model of meningococcal colonization.

Authors:  Kyungcheol Yi; David S Stephens; Igor Stojiljkovic
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

Review 7.  An evaluation of emerging vaccines for childhood meningococcal disease.

Authors:  Debajeet Choudhuri; Tanvir Huda; Evropi Theodoratou; Harish Nair; Lina Zgaga; Rachel Falconer; Ivana Luksic; Hope L Johnson; Jian Shayne F Zhang; Shams El Arifeen; Christopher B Nelson; Ray Borrow; Harry Campbell; Igor Rudan
Journal:  BMC Public Health       Date:  2011-04-13       Impact factor: 3.295

Review 8.  Prospects for eradication of meningococcal disease.

Authors:  Simon Nadel
Journal:  Arch Dis Child       Date:  2012-09-15       Impact factor: 3.791

Review 9.  Importance of circulating antibodies in protection against meningococcal disease.

Authors:  Kim S Erlich; Blaise L Congeni
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452

10.  Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.

Authors:  Markus Knuf; Olivier Romain; Klaus Kindler; Uta Walther; Phu-My Tran; Heidemarie Pankow-Culot; Thomas Fischbach; Dorothee Kieninger-Baum; Véronique Bianco; Yaela Baine; Jacqueline Miller
Journal:  Eur J Pediatr       Date:  2013-01-11       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.